Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Cost of Revenue (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Cost of Revenue for 16 consecutive years, with $11.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 3.16% to $11.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.7 million, a 4.34% increase, with the full-year FY2024 number at $49.2 million, up 28.03% from a year prior.
  • Cost of Revenue was $11.3 million for Q3 2025 at Xtant Medical Holdings, up from $11.1 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $12.7 million in Q1 2025 to a low of $4.5 million in Q1 2021.
  • A 5-year average of $8.8 million and a median of $8.7 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: decreased 13.82% in 2021, then surged 89.88% in 2023.
  • Xtant Medical Holdings' Cost of Revenue stood at $7.1 million in 2021, then grew by 11.63% to $7.9 million in 2022, then surged by 42.49% to $11.2 million in 2023, then rose by 4.03% to $11.7 million in 2024, then fell by 3.6% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Cost of Revenue are $11.3 million (Q3 2025), $11.1 million (Q2 2025), and $12.7 million (Q1 2025).